A meta-analysis of 17 animal studies found that liraglutide partially reverses bone loss in osteoporosis models regardless of diabetes status, working through Wnt and AMPK pathways to promote bone-building and suppress bone-destroying cells.
17 animal studiesConsistently showed liraglutide improved bone parameters in both diabetic and non-diabetic osteoporosis models
What the researchers found
Across 17 animal studies, liraglutide improved bone imaging parameters, bone pathology, and bone maximum load while favorably altering bone metabolism markers, working through Wnt, AMPK/PGC1α, and OPG/RANKL/RANK pathways.
Why it matters
Osteoporosis and diabetes frequently coexist, especially in older adults. If liraglutide directly strengthens bone in addition to controlling blood sugar, it could become a dual-purpose treatment — and the bone benefits may extend to non-diabetic osteoporosis patients as well.
The numbers in context
Improved bone mineral density, bone-related imaging parameters, and serum bone metabolism markers in both diabetic and non-diabetic osteoporosis models.
How the study worked
Systematic review and meta-analysis of 17 animal studies from 8 databases (searched through April 2024). Risk of bias assessed using CAMARADES 10-item checklist; data analyzed with RevMan 5.3.
Who was studied
Animal osteoporosis models with and without diabetes
What this study cannot tell us
All evidence comes from animal models — rodent bone biology differs from humans. Study quality was moderate (average 5.47/10), and many studies lacked blinding and sample size calculations. Human clinical trials specifically measuring bone outcomes with liraglutide are still needed.
How to read the evidence
Preliminary evidence based on a meta-analysis of animal studies. While the pooled animal data is compelling, no human clinical trial evidence for bone-specific outcomes is included.
When this study was published
Published in 2024, with literature search through April 2024; represents the most current preclinical evidence.
The bigger picture
GLP-1 receptor agonists are revealing benefits far beyond diabetes. Bone protection adds to a growing list that includes cardiovascular protection, neuroprotection, and kidney benefits. Understanding the bone-specific pathways (Wnt, AMPK) could lead to targeted therapies for osteoporosis that work through entirely different mechanisms than current treatments like bisphosphonates.
Questions still open
- Do these bone-protective effects translate to reduced fracture risk in human liraglutide users?
- What dose and duration of liraglutide treatment is needed for clinically meaningful bone density improvements?
- Do other GLP-1 agonists like semaglutide share the same bone-protective mechanisms?
Common questions
Could liraglutide replace current osteoporosis medications?
Does liraglutide help bones only in diabetic animals, or in all osteoporosis models?
Read the original research
Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.
Frontiers in endocrinology, 15, 1378291
Citation
Wu, Zongyi; Deng, Wei; Ye, Yiming; Xu, Jie; Han, Deyu; Zheng, Yu; Zheng, Qun. (2024). Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.. Frontiers in endocrinology, 15, 1378291. https://doi.org/10.3389/fendo.2024.1378291